Massive third-party allocation capital increase for rehabilitation... risk of 88% dilution for existing shareholders
Event: UNION KOREA PHARM issued 60 million shares (price 500 won) via third-party allocation, raising 30 billion won. This is a massive capital increase of about 758% compared to existing shares.
Reason: The capital increase was conducted under the rehabilitation plan approved by the court in September 2025, aiming to complete the rehabilitation process and normalize operations.
Risk: The issuance price of 500 won is approximately 82% below the current market price of 2,725 won, severely diluting existing shareholders' equity. The large share supply upon listing will exert strong downward pressure on the stock price.
Shareholder Impact: Existing shareholders' stake shrinks to about 11.6%, effectively transferring control and most value to new investors. Minority shareholders face inevitable significant losses.
[AI Comprehensive Analysis]This capital increase is an unavoidable step to end rehabilitation, but it causes extreme dilution for existing shareholders. Given the deep discount and massive size, a sharp short-term price drop is highly likely, and the lack of investor protection measures is concerning.
KOSDAQ Filing Information
Filing: Securities Issuance Result (Voluntary Disclosure) (Third-Party Allotment Rights Offering)